Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration

dc.contributor.author	Chen-Liang, Tzu-Hua
dc.date.accessioned	2025-11-18T12:47:19Z
dc.date.available	2025-11-18T12:47:19Z
dc.date.issued	2021-05
dc.identifier.citation	Chen-Liang TH. Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration. JCM. 11 de mayo de 2021;10(10):2052.
dc.identifier.uri	https://sms.carm.es/ricsmur/handle/123456789/20906
dc.description.abstract	Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic neoplasms characterized by ineffective hematopoiesis and myelodysplasia with a variable spectrum of clinical-biological features that can be used to build a prognostic estimation. This review summarizes the current most widely used prognostic scoring systems and gives a general view of the prognostic impact of somatic mutations in MDS patients.
dc.language.iso	eng
dc.publisher	MDPI
dc.rights	Atribución-NoComercial-SinDerivadas 3.0 España
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/es/	*
dc.title	Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration
dc.type	info:eu-repo/semantics/article
dc.identifier.pmid	34064707
dc.relation.publisherversion	https://www.mdpi.com/2077-0383/10/10/2052
dc.identifier.doi	10.3390/jcm10102052
dc.journal.title	Journal of Clinical Medicine
dc.identifier.essn	2077-0383